Regenxbio (RGNX) Short term Debt (2014)

Regenxbio (RGNX) recorded quarterly Short term Debt of $1.4 million in Q4 2014.

Regenxbio (RGNX) Short term Debt (2014) Analysis & Trends

Regenxbio's Short term Debt history runs 1 years deep, the most recent figure standing at $1.4 million for Q4 2014.

In Q4 2014, Short term Debt changed N/A year-over-year to $1.4 million; the TTM figure through Dec 2014 stood at $1.4 million (changed N/A YoY), while the FY2014 annual figure was $1.4 million, changed N/A from the prior year.
Short term Debt was $1.4 million for Q4 2014 at Regenxbio.
In the past five years, Short term Debt ranged from a high of $1.4 million in Q4 2014 to a low of $1.4 million in Q4 2014.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn
9	Abivax	94.37 Bn	94.37 Bn	-
10	Regenxbio	315.11 Mn	85.04 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2014	1.42 Mn